122 related articles for article (PubMed ID: 37840516)
1. CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan.
Muley T; Schneider MA; Meister M; Thomas M; Heußel CP; Kriegsmann M; Holdenrieder S; Wehnl B; Rolny V; Mang A; Gerber R; Herth F
Tumour Biol; 2024; 46(s1):S163-S175. PubMed ID: 37840516
[TBL] [Abstract][Full Text] [Related]
2. Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.
Mang A; Zou W; Rolny V; Reck M; Cigoianu D; Schulze K; Holdenrieder S; Socinski MA; Shames DS; Wehnl B; Patil NS
Tumour Biol; 2024; 46(s1):S177-S190. PubMed ID: 37545290
[TBL] [Abstract][Full Text] [Related]
3. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
[TBL] [Abstract][Full Text] [Related]
4. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
6. Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer.
He L; Teng Y; Jin B; Zhao M; Yu P; Hu X; Zhang J; Li S; Gao Y; Liu Y
BMC Cancer; 2010 Dec; 10():681. PubMed ID: 21156055
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
8. The Association of Carcinoembryonic Antigen and Cytokeratin-19 Fragments 21-1 Levels with One-Year Survival of Advanced Non-Small Cell Lung Carcinoma at Cipto Mangunkusumo Hospital: A Retrospective Cohort Study.
Rumende CM; Sugianto GCK; Rinaldi I; Muhadi M
Acta Med Indones; 2020 Apr; 52(2):140-146. PubMed ID: 32778628
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer.
Cho A; Hur J; Hong YJ; Lee HJ; Kim YJ; Hong SR; Suh YJ; Im DJ; Kim YJ; Lee JS; Shim HS; Choi BW
Tumour Biol; 2016 Mar; 37(3):3205-13. PubMed ID: 26432331
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008-2022 update.
Trulson I; Holdenrieder S
Tumour Biol; 2024; 46(s1):S111-S161. PubMed ID: 37927288
[TBL] [Abstract][Full Text] [Related]
11. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
13. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients.
Pujol JL; Boher JM; Grenier J; Quantin X
Lung Cancer; 2001; 31(2-3):221-31. PubMed ID: 11165401
[TBL] [Abstract][Full Text] [Related]
14. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
Tumour Biol; 2024; 46(s1):S191-S206. PubMed ID: 38363625
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy.
Svaton M; Blazek J; Krakorova G; Pesek M; Buresova M; Teufelova Z; Vodicka J; Hurdalkova K; Barinova M; Topolcan O
Anticancer Res; 2021 Apr; 41(4):2053-2058. PubMed ID: 33813413
[TBL] [Abstract][Full Text] [Related]
16. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?
Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V
Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116
[TBL] [Abstract][Full Text] [Related]
18. Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
Trulson I; Klawonn F; von Pawel J; Holdenrieder S
Tumour Biol; 2024; 46(s1):S81-S98. PubMed ID: 38277317
[TBL] [Abstract][Full Text] [Related]
19. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
[TBL] [Abstract][Full Text] [Related]
20. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]